What exactly does Mounjaro do inside your body?

Why does hitting two receptors instead of one actually matter?

Most people asking what Mounjaro does have already read that it is a "GIP and GLP-1 receptor agonist" and found that phrase more confusing than helpful. Here is the plain version. GLP-1 is a hormone your gut releases after eating; it signals to your brain that you are full, nudges the pancreas to release insulin, and slows the speed at which your stomach passes food into your intestines. Mounjaro activates GLP-1 receptors in the same way that signal does naturally, but more reliably and for longer, because tirzepatide stays in your system for roughly a week.

GIP is a second gut hormone with overlapping but distinct effects. It also plays a role in appetite regulation and in how efficiently your body stores and burns energy. The science on the combined action is still developing, but the working understanding is that activating both pathways produces a larger appetite-reduction effect than either alone. The detailed mechanism of how Mounjaro works covers the receptor biology more thoroughly if you want to go deeper.

The practical upshot: people on Mounjaro typically find that hunger arrives later, portions feel adequate sooner, and the pull of high-calorie foods eases, not from willpower, but from changes in how the brain receives hunger signals. That is not a marketing line; it is the pharmacology.

What does Mounjaro do to your weight over time, and what does the evidence actually show?

The SURMOUNT-1 trial is the landmark study here: 2,539 adults with obesity (no type 2 diabetes) were randomised across three doses and placebo for 72 weeks. At 15 mg, average body-weight reduction was around 20–21%. To put that in context, most lifestyle interventions produce 3–5% average loss; the best-performing medicines before tirzepatide produced roughly 15%. The SURMOUNT-5 trial then ran Mounjaro head-to-head against semaglutide 2.4 mg (Wegovy) and found tirzepatide produced greater average weight loss, published in the New England Journal of Medicine in 2025.

Two caveats worth saying plainly. First, the trial results are averages, some participants lost considerably more, some less, and a small number did not respond substantially. Second, the benefits appear to depend on continuing treatment; weight can return if the medicine is stopped without lifestyle changes in place. That is not unique to Mounjaro, but it matters for anyone planning around it. If you want a side-by-side look at what the physical changes involve, what Mounjaro does to the body covers that angle specifically.

Eli Lilly's KwikPen delivers a once-weekly dose subcutaneously, abdomen, thigh or upper arm, rotated each time. The pen lives in the fridge (between 2–8°C; the exact room-temperature window is in the Patient Information Leaflet, not something to guess at). Many people keep it in the fridge door and find a weekly routine easy to hold.

Who is Mounjaro designed for, and who should not use it?

The UK licence covers adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal (TA1026) sets the bar for NHS access higher still: BMI 35 or above plus at least one qualifying comorbidity, with a phased rollout that is still expanding through 2026 and 2027. For people who do not yet meet NHS criteria or prefer not to wait, private treatment through a regulated pharmacy is the legal alternative, provided a prescriber confirms suitability first.

A few situations where Mounjaro is not recommended: pregnancy, breastfeeding, or actively trying to conceive; anyone under 18; and people with a personal or family history of medullary thyroid carcinoma or MEN2. Certain gastrointestinal conditions and a history of pancreatitis also require careful prescriber discussion before starting. The common side effects are gastrointestinal, nausea, loose stools, constipation and indigestion are the most frequently reported, most noticeable after starting or a dose increase, and for most people they settle within a couple of weeks. The practical guide to being on Mounjaro covers managing these early weeks in more detail.

For women using oral contraceptives, the NHS advises adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can affect pill absorption. That is specific to Mounjaro; the equivalent caution does not apply to injectable semaglutide. Worth knowing before you start.

Is Mounjaro a prescription medicine, and how does that change how you access it?

Yes. Tirzepatide is a Prescription-Only Medicine under UK law, which means no legitimate seller can supply it without a valid prescription issued following a clinical assessment. It also means it cannot legally be advertised as a product to the public, which is why you will find very little promotional language on responsible pharmacy sites, and why heavy promotional language from an online seller is a red flag. The MHRA has been clear that these medicines are not assessed or intended for quick or cosmetic weight loss, and has pursued enforcement action against counterfeit supply chains selling injectable pens through social media.

The route through a regulated online pharmacy starts with a consultation: your medical history, current medicines, weight and BMI are assessed by a real prescriber. At nume, that review is done by a GPhC-registered Independent Prescriber, a named clinician, not automated software. Identity and current weight are verified, and if treatment is approved, the prescription and pen are dispatched the same day. For anyone thinking about whether the cost stacks up against the NHS route, our honest look at Mounjaro pricing in the UK lays out what private treatment typically involves. A full overview of tirzepatide as a medicine covers the wider clinical picture for anyone researching before a consultation.

If you have read this far and think Mounjaro might suit you, the practical next step is a clinical assessment rather than more reading. Check your eligibility with our prescribers, the consultation is free, and you will get a straight answer from a clinician who has reviewed your details.